Phaseline

Targets › CD133

CD133: drug programs, companies and trials

2 programs from 2 companies in 2 trials: 2 Phase 1; Hematology, Oncology; next expected readout Apr 2027.

Open in Phaseline: the race on CD133, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
National Heart, Lung, and Blood Institute (NHLBI)Omidubicel (formerly CordIn)
Ex vivo expanded umbilical cord blood-derived CD133+ stem and progenitor cells
CD133Phase 1Severe Aplastic AnemiaApr 2027
Tasly PharmaceuticalsP134 cells
CD44/CD133 dual-targeting CAR-T cells
CD44, CD133Phase 1Recurrent Glioblastoma IDH WildtypeFeb 2028

Conditions

Severe Aplastic Anemia (1) Recurrent Glioblastoma IDH Wildtype (1)

Modalities

other (2)

Companies

National Heart, Lung, and Blood Institute (NHLBI) (1) Tasly Pharmaceuticals (1)

Related targets

CD44 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.